12-week open label treatment of refractory bipolar depression (BD) with combination of Depakote ER (DEP) [valproate semisodium] and aripiprazole (AZP)

Trial Profile

12-week open label treatment of refractory bipolar depression (BD) with combination of Depakote ER (DEP) [valproate semisodium] and aripiprazole (AZP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Aripiprazole (Primary) ; Valproate semisodium
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top